CHPG

Overview

CHPG is a selective mGluR5 agonist, and attenuates SO 2 -induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells. CHPG protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the ERK and Akt signaling pathways.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > ERK | Products > Signaling Pathways > Akt | Products > Signaling Pathways > mGluR | Products > Signaling Pathways > NF-κB

Product Information

• Catalog No.: HY-101364
• CAS No.: 170846-74-9
• Molecular Formula: C8H8ClNO3
• Molecular Weight: 201.61
• Purity: 99.51%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source